Polikistik Böbrek Hastalığı Olan Çocukların Endocan Düzeyi

Yıl 2022, Cilt: 16 Sayı: 4, 313 - 317, 07.07.2022

Zehra Aydın , İsmail Selçuk Aygar , Umut Selda Bayrakçı , Mihriban İnözü , Fatma Şemsa Çaycı

https://doi.org/10.12956/tchd.1002968

Öz

Amaç: Otozomal dominant polikistik böbrek hastalığı (ODPKB), hipertansiyon ve böbrek yetmezliği ile karakterize yaygın görülen bir böbrek hastalığıdır. Son zamanlarda endotel disfonksiyonu biyobelirteçlerinden olan endocanın birçok böbrek hastalığında artabileceği vurgulanmıştır. Böbrek yetmezliği olan hipertansif ODPKB’li erişkin hastalarda da yüksek endocan seviyeleri bildirilmiştir. Ancak, çocuklar üzerinde yapılan çalışmalar sınırlıdır. Bu çalışmada, normal böbrek fonksiyonu olan normotansif ODPKB’li çocuklarda serum endocan düzeylerini araştırdık.

Gereç ve Yöntemler: Çalışmaya, hasta grubu olarak hipertansiyonu ve böbrek yetmezliği olmayan 20 ODPBH’li çocuk ve kontrol grubu olarak yaş ve cinsiyet açısından benzer 20 sağlıklı çocuk dahil edildi. Serum endocan seviyeleri, enzime bağlı immünosorbent tahlil teknikleri ile belirlendi ve iki grup arasında karşılaştırıldı.

Bulgular: Hastaların yaş ortalaması 9.9±4.12 yıl, kontrol grubunun yaş ortalaması 10.2±3.83 yıldı. Cinsiyet, yaş ve VKİ açısından iki grup arasında anlamlı fark yoktu (sırasıyla p=0.751, p=0.813, p=0.781). Gruplar arasında Lökosit (p=0.449), hemoglobin (p=0.337), trombosit (p=0.134), serum ürik asit (p=0.671), serum kreatinin (p=0.074) seviyeleri, ve eGFR (p=0.459) düzeyleri açısından anlamlı fark bulunmadı. PKB grubunda ortalama serum endocan düzeyi 345.8±169.5 pg/ml, kontrol grubunda 448.61±258.2 pg/ml’di. Serum endocan seviyeleri gruplar arasında değişmedi (p=0.159).

Sonuç: Erişkin ODPKB hastalarından farklı olarak, bu çalışmada hipertansiyon ve böbrek yetmezliği olmayan ODPKB’li çocuklarda serum endocan düzeyinin normal olduğu saptandı.

Anahtar Kelimeler

Çocuk, Polikistik böbrek hastalığı, Endocan

Destekleyen Kurum

Ankara Doşkapı Çocuk hematoloji ve onkoloji hastanesi etik kurul

Proje Numarası

2019-155

Endocan Levels in Children with Polycystic Kidney Disease

Öz

Objective: Autosomal dominant polycystic kidney disease (ADPKD) is a common renal disorder that is characterized by hypertension and renal failure. Recently, it has been emphasized that endocan which is an endothelial dysfunction biomarker, could increase in many renal diseases. High endocan levels have also been reported in hypertensive ADPKD adult patients with renal failure. However, studies are limited on children. In this study, we investigated the serum endocan levels in normotensive ADPKD children with normal renal function.

Material and Methods: The study consisted of 20 ADPKD children without hypertension and renal failure as a patient group, and 20 healthy age- and sex-matched children as a control group. Serum endocan levels were determined by enzyme-linked immunosorbent assay techniques and compared between the two groups.

Results: The mean age of patients was 9.9±4.12 years, and the mean age of the control group was 10.2±3.83 years. There was no significant difference between the two groups in terms of gender, age, and BMI (p=0.751, p=0.813, p=0.781, respectively). The leukocyte (p=0.449), hemoglobin (p=0.337), platelets (p=0.134), serum uric acid (p=0.671) and serum creatinine (p=0.074) levels, eGFR (p=0.459) were not significantly differed between groups. The mean serum endocan level in the PKD group was 345.8±169.5 pg/ml, and in the control group was 448.61±258.2 pg/ml. Serum endocan levels did not change between groups (p=0.159).

Conclusion: Unlike the adult ADPKD patients, this study suggested that serum endocan level was normal in children with ADPKD without hypertension and renal failure.

Anahtar Kelimeler

child, polycystic kidney disease, Endocan

Proje Numarası

2019-155

Kaynakça

• 1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287–301.
• 2. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2009; 60: 321–37.
• 3. Rahbari-Oskoui F, Williams O, Chapman A. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2014; 29: 2194–201.
• 4. Karihaloo A, Koraishy F, Huen SC, Lee Y,Merrick D, Caplan MJ, et al. Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 2011; 22: 1809–14.
• 5. Hiesberger T, Gourley E, Erickson A, Koulen P, Ward CJ, Masyuk TV. et al. Proteolytic cleavage and nuclear translocation of fibrocystin is regulated by intracellular Ca2+ and activation of protein kinase C. J Biol Chem 2006; 281: 34357–64.
• 6. Raptis V, Bakogiannis C, Loutradis C, Boutou AK, Lampropoulou I, Intzevidou E. et al. Levels of Endocan, Angiopoietin-2, and Hypoxia Inducible Factor-1a in patients with autosomal dominant polycystic kidney disease and different levels of renal fuction. Am J Nephrol 2018; 47: 231–8.
• 7. Messchendorp AL, MEijer E, Boertien WE, Engels GE, Casteleijn NF, Spithoven EM. et al. Urinary biomarkers to identify autosomal dominant polycystic kidney disease patients with a high likelihood of disease progression. Kidney Int Rep 2018; 3: 291-301.
• 8. Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W. et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996; 271: 20458–64.
• 9. Gimpel C, Bergmann C, Bockenhauer D, Breysem L, Cadnapaphornchai MA, Cetiner M. et al. International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. Nature Reviews Nephrology 2019;15, 713-26.
• 10. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Caroll AE, Daniels SR. et al.; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017; 140: e20171904
• 11. Lee YH, Kim SJ, Kim SY, Kim YG, Moon JY, Jeong KH. et al. Plasma endocan level and prognosis of immunoglobulin A nephropathy. Kidney Res Clin Pract 2016; 35: 152-9
• 12. Yilmaz MI, Siriopol D, Saglam M, Kurt YG, Unal HU, Eyileten T, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int 2014; 86: 1213-20.
• 13. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Kurtoglu E, Demir M. et al. Endocan A novel inflammatory indicator in newly diagnosed patients with hypertension: A pilot study. Angiology 2014; 65: 773–7.
• 14. Ekinci I, Buyukbaba M, Cinar A, Tunc M, Cebeci E, Gursu M. et al. Endothelial Dysfunction and Atherosclerosis in Patients With Autosomal Dominant Polycystic Kidney Disease. Cureus 2021; 13: e13561.
• 15. Li S, Wang L, Wang C, Wang Q, Yang H, Liang P. et al. Detection on dynamic changes of endothelial cell specific molecule1 in acute rejection after renal transplantation. Urology 2012; 80: 738.e1–738.e8.